RCTs will guide you through conception, implementation and publication of studies performed either from alone or paired secondary data (i.e. French Claim Data base SNDS/ registry) by probabilistic or direct pairing. Those data may come from:
| The French Claim Data base (SNDS : DCIR, EGB, PMSI) | ||
| Clinical trials | ||
| Registry or observational studies databases | ||
| Connected devices | ||
| Prospective studies | ||
| Any real-world evaluation: efficiency, good use, safety, therapeutic strategy, etc. | ||
| Your Market Access Studies: Targeted or Reached Population, disease burden | ||
| Your cost studies for the development of models for the CEESP | ||
| Your post-registration studies at the request of authorities | ||
| In the dynamic analysis of healthcare pathways with data-science and AI methods | ||
| In pharmaco-economics | ||
| In epidemiology and pharmacoepidemiology (indicators for drug exposure) | ||
| Dans la lecture de l’information codée dans le SNDS et l’élaboration d’algorithmes de sélection de populations et d’identification d’évènements d’intérêt | ||
| In reading coded information in the SNDS and in developing algorithms for selecting populations and identifying events of interest In Big Data analysis, with over 30 years of experience in biometry and mastery of analytical tools that will optimize the use of secondary data (propensity score, modelling, clustering) |
||
Based on the guidelines published by the Health Authorities and depending on the study issue and on the proposed strategy, RCTs supports the pharmaceutical firms and medical device companies in choosing the type of assessment (cost-benefit analysis , cost-effectiveness analysis) and of model (Markov models, Discrete Event Simulation models, decision trees, etc.), whether by adapting an existing model or by creating a new one, in agreement with a Scientific Committee.
RCTs’ proposals are based on rigorous literature review and particular attention is paid to the mobilization of French data: INSEE data, use of French Claim Data base databases (DCIR, PMSI or EGB according to the study objectives ) for disease cost studies, but also for good use studies, or for data from an health-economic evaluation.
RCTs also supports the pharmaceutical firms and medical device companies in preparing the submission file to obtain an efficiency opinion from the Commission for Economic Evaluation and Public Health (CEESP).